Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Disease area: Interstitial lung diseases

Abstract

Background: An oxidant-antioxidant imbalance may be associated with the disease process in Idiopathic pulmonary fibrosis (IPF). N-acetylcystein might contribute to a reversal of the oxidant-antioxidant imbalance. The inhalation of N-acetylcystein might be the best way of reaching N-acetylcystein to respiratory epithelial lining fluid. Furthermore, the efficacy of inhaled N-acetylcystein in patients with secondary interstitial pneumonia remains unclear.Aim: To assesse the clinical efficacy of inhaled N-acetylcystein therapy in patients with interstitial pneumonia.Methods: The study design was a prospective, single-arm study of the clinical effects of inhaled N-acetylcystein in patients with interstitial pneumonia who visited one institute in Saitama, Japan, between January 1 and December 31, 2013.Results: A total of 40 patients were included. The patients with interstitial pneumonia were diagnosed as follows: IPF, 29 cases; idiopathic nonspecific interstitial pneumonia, 5 cases; connective tissue disease, 5 cases; and chronic hypersensitive pneumonitis, 1 case. The mean change in FVC during the 6 months after N-acetylcystein therapy was -10 mL. The effect of N-acetylcystein was only examined in patients (n = 28) who had conducted a respiratory function test at 6 months before the initiation of therapy. The mean change in FVC during 6 months prior to the N-acetylcystein therapy was -127 mL, while the mean change in FVC during 6 months after the initiation of therapy was -19 mL. The absolute serum level of KL-6 decreased significantly from 1372 U/mL to 1065 U/mL after the therapy. Conclusions: These results showed that inhaled N-acetylcystein had a beneficial effect in patients with interstitial pneumonia.

Rating:

Share or cite this content

Citations should be made in the following way:
R. Okuda, T. Ohba, T. Nishizawa, R. Kawabe, K. Honda, M. Amano, H. Matsushima (Saitama, Japan). LATE-BREAKING ABSTRACT: Efficacy of inhaled N-acetylcystein in patients with interstitial pneumonia. Eur Respir J 2014; 44: Suppl. 58, 4500

Member's Comments

No comment yet.

Related content which might interest you: Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Idiopathic non-specific interstitial pneumonia (iNSIP): do the patients develop connective tissue disease (CTD) during follow-up? Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 "Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease" Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 The prognostic factor in patients with myositis-associated interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Clinical course and outcome of vasculitis related interstitial lung disease Source: International Congress 2014 – ILDs 2 Year: 2014 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 The clinical features of 13 patients with interstitial pneumonia with positive anti-glycyl-tRNA synthetase autoantibodies Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Study of factors affecting mortality in ILD cases over 2 years Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Neoplasia in patients with ILD; shortened survival Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 OSA with intertitial lung diseases Source: International Congress 2016 – Effect of sleep apnoea on life-span and comorbidities Year: 2016 Safety and advantages of VATS biopsy in diagnosis of interstitial lung disease Source: International Congress 2015 – Challenges in surgery for non-malignant disorders: pleural mediastinal and tracheal problems, congenital disorders Year: 2015 LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis Year: 2014